AI and biotech
Drug discovery and development is time-intensive, expensive and laden with risk. Identifying the right drug targets is crucial for increasing the probability of success, but traditional target identification and validation often take years, and a target is only fully validated once a drug based on i…
Accelerating Leigh syndrome drug discovery through deep learning screening in brain organoids.
2026-04-20
Leigh syndrome (Leigh) is an untreatable mitochondrial disorder characterized by lactic acidosis and basal ganglia and midbrain pathology, leading to psychomotor regression and early death. We previously uncovered impaired neuronal morphogenesis in Leigh cerebral organoids carrying SURF1 gene varian…
Gene editing
Intracellular delivery of genetic coding molecules is a critical step in both fundamental cell biology and the development of cell and gene therapies. With the emergence of diverse genetic coding molecules, next-generation cell engineering increasingly relies on delivering multiple types of payloads…
Genomics
SMARCB1-deficient renal medullary carcinoma (RMC) is an aggressive kidney cancer lacking mechanism-directed therapies. We conducted a single-center, single-arm, phase II study (NCT03587662) testing the proteasome inhibitor ixazomib combined with gemcitabine and doxorubicin….
Immunotherapy
The prevalence of cancers has actually increased during the last few decades, affecting almost all human societies. Despite progress in therapeutic protocols, cancer is still the main cause of global human mortality. Although the advancement of modern immunotherapeutic approaches can increase the su…
Fibrosis is a severe pathological outcome of many chronic diseases, yet the therapeutic potential of targeting the altered major histocompatibility complex (MHC) class I immunopeptidome remains largely unexplored. Here we characterized the MHC class I immunopeptidomes from both fibrotic foci of huma…
The tumor immune microenvironment (TIME) in non-small cell lung cancer (NSCLC) histopathology contains morphological and molecular characteristics predictive of immunotherapy response. Computational quantification of TIME characteristics, such as cell detection and tissue segmentation, can support b…
Integrin beta-6 (IB6) is highly expressed in non-small cell lung cancer (NSCLC) and other solid tumors and potentially associated with poor outcomes. Sigvotatug vedotin (SV), a novel IB6-directed antibody-drug conjugate, demonstrated acceptable safety and encouraging antitumor activity in dose escal…
Current image-based deep learning models that predict the benefits of immunotherapy in non-small cell lung cancer (NSCLC) require high-performance hardware. We aimed to develop and externally validate a clinician-operable prognostic model that integrates clinical and imaging data in a format usable …
Ovarian cancer (OC) is a leading cause of gynecological cancer-related mortality. Management remains challenging as the disease frequently presents with intra-abdominal metastases at diagnosis, standard therapies can be associated with severe complications and disease recurrence is common. While cel…
The ovarian tumor microenvironment (TME) is highly immunosuppressive, limiting immunotherapy effectiveness. We investigated whether the composition, ratios, and polarization of infiltrating immune cells provide prognostic value in ovarian cancer (OC). Our analysis revealed that immune ratios, includ…
Harnessing Neoantigen-specific T Cells for Precision Immunotherapy in Hematologic Malignancies.
2026-04-20
Antigen-specific T-cell immunotherapies are transforming the treatment landscape of hematologic malignancies. Neoantigen-specific therapies that exploit the ability of endogenous T-cell receptors (TCRs) to recognize tumor-derived peptides in a human leukocyte antigen (HLA)-restricted context differ …
Immune checkpoint inhibitors (ICIs) can induce long-term survival and even cancer cure in several cancers. Mixture cure models (MCMs) estimate the fraction of long-term survivors and cured patients but have not been applied in HCC….
Immune cell therapy has emerged as a highly promising modality in cancer immunotherapy. Effective in vivo cell tracking is essential for the real-time assessment of cell distribution, viability, and proliferation, providing critical insights into both fundamental research and clinical translation. H…
Neoadjuvant chemoimmunotherapy improved pathological complete response (pCR) rates in early triple-negative breast cancer (TNBC). However, the relationship between immune-related adverse events (irAEs) and treatment response remains unclear. This study evaluated the association between the developme…
The prognosis for patients with recurrent or metastatic cervical cancer (r/mCC) remains challenging, with a 5-y survival rate of approximately 17%. Although first-line treatment has evolved from traditional single-agent chemotherapy to combination regimens that incorporate targeted therapy and immun…